Portfolio Lab

Jin Medical International Ltd.

  • Stock
  • Ticker ZJYL
  • NASDAQ

Performance, volatility and drawdowns of Jin Medical International Ltd. since 03/2023, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.

1-year return
−35.3%
Return p.a. since 03/2023
−20.9%
Volatility p.a.
506.5%
Largest decline
−99.3%

Performance

ZJYLGlobal equities (VT)

$10,000 grew to $1,405. Global equities (VT): $15,235.

Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.

Declines from the peak

Lowest point −99.3% in 07/2026, measured from the peak in 01/2024. The old peak has not been reached again yet.

Annual returns

Best year 2025 at −71.7%, weakest 2024 at −93.7%. 0 of 2 full years were positive. * partial year.

Compared with Global equities

Since 03/2023ZJYLGlobal equities (VT)
Return p.a.−20.9%+15.7%
Volatility p.a.506.5%12.8%
Largest decline−99.3%−16.5%
Return per unit of risk-0.041.22
$10,000 grew to$4,252$17,003

Bold: the better value in each row. Return per unit of risk: return p.a. divided by volatility p.a. Correlation of monthly returns with Global equities: 0.20 (1 would mean they moved in lockstep).

More stocks of similar size

Test ZJYL in your own portfolio

Mix it with other securities, set recurring investments and costs, compare against a broad equity ETF. No account needed.

Open in backtest

Frequently asked questions

How has ZJYL performed since 03/2023?

$10,000 grew to $4,252 by 20 Nov 2026, which is −20.9% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.

How volatile is ZJYL?

Volatility was 506.5% per year, measured on monthly returns. The largest decline from a peak was −99.3%, with the low in 07/2026.

How does ZJYL compare with a broad equity ETF?

Over the same period Global equities (VT) returned +15.7% per year at 12.8% volatility, ZJYL returned −20.9% at 506.5%. The correlation of monthly returns was 0.20; 1 would mean they moved in lockstep.

Which currency are the figures in?

In US dollars, the currency of the US listing.

Reference data of securities: source ESMA (FIRDS reference data) and SEC (EDGAR).

Not investment advice: results in Portfolio Lab are model calculations based on historical data and your inputs. Past performance is not a reliable indicator of future results.